The primary objective will be to evaluate the efficacy of GlycoDual in reducing fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG) levels compared to placebo after 90 days of treatment.
Secondary objectives are to estimate:
* the change of insulin sensitivity (HOMA-IR) * the change of uricemia after 90 days of supplementation compared to placebo.
Safety objectives: Collection of the adverse events not related, related or possibly related to the study products.
body mass index (BMI) 25.0-29.9 kg/m2
FPG levels between 100 and 125 mg/dl [IFG diagnosed after Oral Glucose Tolerance Test (OGTT)]
HOMA-IR > 2.5
subjects able to understand the informed consent and sign it before enrollment in the study
personal history of cardiovascular disease or equivalent risk factors
obesity (BMI ≥ 30 kg/m²)
taking hypoglycemic drugs or supplements that affect glycemic metabolism
diabetes mellitus or IGT